Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

OTHER 96 INDUSTRY 27 NIH 10 NETWORK 2 INDIV 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Proflavine 9 pembrolizumab 2 Tacrolimus 2 Pyridostigmine Bromide 2 Prednisone 2 Microbial Collagenase 2 sargramostim 1 plerixafor 1 pegfilgrastim 1 olaparib 1 nilotinib 1 macimorelin 1 keyhole-limpet hemocyanin 1 ethyl pyruvate 1 compound W 1 blinatumomab 1 Watchful Waiting 1 Uracil 1 Tegafur 1 Surgical Procedures, Operative 1 Steroids 1 Sodium Chloride 1 Sirolimus 1 Salicylates 1 Peptides 1 PM 01183 1 Mycophenolic Acid 1 Monatide (IMS 3015) 1 Mifepristone 1 Methylprednisolone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDIV × blinatumomab × Clear all

NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡